This is the first study to evaluate the concentrations of SFRP1, SFRP2, and SFRP5 in tumour and non-tumour (NT) samples from patients with primary NSCLC, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Here, SFRP1 is linked to adenocarcinoma.